ANTHEM

Anthem Biosciences Share Price

 

 

Invest in Anthem Biosciences with 3.37X leverage

Invest with MTF

Performance

  • Low
  • ₹669
  • High
  • ₹690
  • 52 Week Low
  • ₹579
  • 52 Week High
  • ₹874
  • Open Price₹678
  • Previous Close₹675
  • Volume249,764
  • 50 DMA₹642.48
  • 100 DMA₹684.44
  • 200 DMA-

Investment Returns

  • Over 1 Month + 7.46%
  • Over 3 Month -2.85%
  • Over 6 Month -7.25%
  • Over 1 Year + 18.72%

Smart Investing Starts Here Start SIP with Anthem Biosciences for Steady Growth!

Invest Now

Anthem Biosciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 78.4
  • PEG Ratio
  • -
  • Market Cap Cr
  • 38,011
  • P/B Ratio
  • 13.8
  • Average True Range
  • 24.11
  • EPS
  • 8.95
  • Dividend Yield
  • 0
  • MACD Signal
  • -7.42
  • RSI
  • 66.37
  • MFI
  • 71.54

Anthem Biosciences Financials

Anthem Biosciences Technicals

EMA & SMA

Current Price
₹676.70
+ 1.8 (0.27%)
pointer
  • Bearish Moving Average 2
  • Bullish Moving Average 11
  • 20 Day
  • ₹628.04
  • 50 Day
  • ₹642.48
  • 100 Day
  • ₹684.44
  • 200 Day
  • -

Resistance and Support

678.57 Pivot Speed
  • R3 709.13
  • R2 699.57
  • R1 688.13
  • S1 667.13
  • S2 657.57
  • S3 646.13

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Anthem Biosciences is a Contract Research and Innovation Service Provider (CRISP) in Bangalore, India, with two facilities supporting over 1,000 researchers. It offers R&D, manufacturing, and testing of biologics, small molecules, and nutraceuticals, serving global pharma, biotech, and wellness companies.

Anthem Biosciences Ltd has an operating revenue of Rs. 1,996.59 Cr. on a trailing 12-month basis. An annual revenue growth of 30% is outstanding, Pre-tax margin of 36% is great, ROE of 18% is exceptional. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is trading below to its 200DMA and around 5% up from its 50DMA. It needs to take out the 200DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 22% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 4 which is a POOR score indicating inconsistency in earnings, a RS Rating of 53 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 106 indicates it belongs to a poor industry group of Medical-Biomed/Biotech and a Master Score of D is close to being the worst. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Anthem Biosciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2026-02-05 Quarterly Results
2025-11-08 Quarterly Results
2025-08-13 Quarterly Results

Anthem Biosciences F&O

Anthem Biosciences Shareholding Pattern

74.69%
6.89%
0.44%
1.37%
0%
9.6%
7.01%

Anthem Biosciences FAQs

Anthem Biosciences share price is ₹676 As on 11 February, 2026 | 01:40

The Market Cap of Anthem Biosciences is ₹38011.2 Cr As on 11 February, 2026 | 01:40

The P/E ratio of Anthem Biosciences is 78.4 As on 11 February, 2026 | 01:40

The PB ratio of Anthem Biosciences is 13.8 As on 11 February, 2026 | 01:40

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23